Treatment of unfit patients with advanced non-small-cell lung cancer: Definition criteria according an expert panel

Clinical Lung Cancer

Volumn 16, Issue 6, 2015, Pages 399-405

  De Marinis, Filippo ^a   Bria, Emilio ^b   Baas, Paul ^c   Tiseo, Marcello ^d   Camerini, Andrea ^e   Favaretto, Adolfo Gino ^f   Gridelli, Cesare ^g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e ISTITUTO TOSCANO TUMORI   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g S G MOSCATI HOSPITAL   (Italy)

Author keywords

Chemotherapy; Lung cancer; Review; Treatment; Unfit

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN;

ADVANCED CANCER; AGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER SUPPORT; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; CONSENSUS; FITNESS; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MENTAL DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROPATHY; NON SMALL CELL LUNG CANCER; PERFORMANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; AGED; ALGORITHM; CARCINOMA, NON-SMALL-CELL LUNG; FRAIL ELDERLY; LUNG NEOPLASMS; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FRAIL ELDERLY; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 84944357384     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.04.008     Document Type: Review

References (40)

1. C. Allemani, H.K. Weir, H. Carreira, and et al. Global surveillance of cancer survival, 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet 385 2015 977 1010
2. J.D. Patel, L. Krilov, S. Adams, and et al. Clinical cancer advances, 2013. Annual report on progress against cancer from the American Society of Clinical Oncology J Clin Oncol 32 2014 129 160
3. A.G. Pallis, C. Gridelli, U. Wedding, and et al. Management of elderly patients with NSCLC: updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology Ann Oncol 25 2014 1270 1283
4. M.D. Galsky, N.M. Hahn, J. Rosenberg, and et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy J Clin Oncol 29 2011 2432 2438
5. M. Reck, S. Popat, N. Reinmuth, and et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii27 iii39
6. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group J Natl Cancer Inst 91 1999 66 72
7. C. Gridelli, F. Perrone, C. Gallo, and et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362 372
8. E. Quoix, G. Zalcman, J.P. Oster, and et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Lancet 378 2011 1079 1088
9. D.S. Ettinger, D.E. Wood, W. Akerley, and et al. Non-small cell lung cancer, version 1.2015 J Natl Compr Canc Netw 12 2014 1738 1761
10. A. Inoue, K. Kobayashi, K. Usui, and et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
11. A. Vergnenegre, R. Corre, H. Lena, and H. Le Caer How old is "too old" for translational research? Transl Lung Cancer Res 3 2014 116 119
12. M.A. Socinski, T. Evans, S. Gettinger, and et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer. 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines Chest 143 2013 e341S e368S
13. D.H. Johnson, J.H. Schiller, and P.A. Bunn Jr. Recent clinical advances in lung cancer management J Clin Oncol 32 2014 973 982
14. C. Gridelli Elderly lung cancer patients: what treatment strategies? Expert Rev Anticancer Ther 7 2007 1331 1334
15. C. Gridelli, M. Aapro, A. Ardizzoni, and et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel J Clin Oncol 23 2005 3125 3137
16. C. Gridelli Chemotherapy of non-small cell lung cancer in the elderly Lung Cancer 38 suppl 3 2002 S67 S70
17. C. Gridelli Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 38 suppl 2 2002 S45 S50
18. C. Gridelli, A. Ardizzoni, T. Le Chevalier, and et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European experts panel Ann Oncol 15 2004 419 426
19. V. Gebbia, D. Galetta, and F. De Marinis Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials Ann Oncol 16 suppl 4 2005 iv123 iv131
20. E. Radzikowska, P. Glaz, and K. Roszkowski Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases Ann Oncol 13 2002 1087 1093
21. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 2008 4617 4625
22. P. Maione, F. Perrone, C. Gallo, and et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian Lung Cancer in the Elderly study J Clin Oncol 23 2005 6865 6872
23. C.P. Belani, and F. Fossella Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326) Cancer 104 2005 2766 2774
24. K. Kelly, S. Giarritta, W. Akerley, and et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology trials 9509 and 9308. Paper presented at: American Society of Clinical Oncology (ASCO) annual meeting J Clin Oncol 2001 329a
25. C. Gridelli, P. Maione, A. Illiano, and et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies J Clin Oncol 25 2007 4663 4669
26. T. Abe, K. Takeda, Y. Ohe, and et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the Intergroup Trial JCOG0803/WJOG4307L J Clin Oncol 2015
27. C. Gridelli, A. Rossi, M. Di Maio, and et al. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer Clin Lung Cancer 15 2014 166 170
28. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group BMJ 311 1995 899 909
29. C.J. Sweeney, J. Zhu, A.B. Sandler, and et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 92 2001 2639 2647
30. T. Le Chevalier, D. Brisgand, J.Y. Douillard, and et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients J Clin Oncol 12 1994 360 367
31. J.C. Soria, D. Brisgand, and T. Le Chevalier Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12 2001 1667 1670
32. R.C. Lilenbaum, J.E. Herndon 2nd, M.A. List, and et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730) J Clin Oncol 23 2005 190 196
33. M. Zukin, C.H. Barrios, J.R. Pereira, and et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2 J Clin Oncol 31 2013 2849 2853
34. A. Morabito, V. Gebbia, M. Di Maio, and et al. Randomized phase III trial of gemcitabine and cisplatin vs gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study Lung Cancer 81 2013 77 83
35. A. Gajra, A.S. Marr, and A.K. Ganti Management of patients with lung cancer and poor performance status J Natl Compr Canc Netw 12 2014 1015 1025
36. R. Corre, C. Chouaid, L. Greillier, and et al. Phase III, randomized, multicenter study comparing in elderly patients (≥ 70 years) with stage IV non small-cell lung cancer (NSCLC) a standard strategy of treatment allocation (carboplatin based bi-therapy or monotherapy with docetaxel) based on performance status (PS) and age with an experimental strategy allocating the same chemotherapies or best supportive care (BSC) according to a comprehensive geriatric assessment (CGA) - study ESOGIA-GFPC-GECP 08-02. In: 15th World Conference on Lung Cancer J Thorac Oncol 2013 S192 S193
37. L. Balducci The geriatric cancer patient: equal benefit from equal treatment Cancer Control 8 2001 1 25
38. L. Balducci Geriatric oncology Crit Rev Oncol Hematol 46 2003 211 220
39. A.K. Guddati, P.S. Joy, and C.P. Marak Dose adjustment of carboplatin in patients on peritoneal dialysis Med Oncol 31 2014 946
40. A.K. Guddati, P.S. Joy, and C.P. Marak Dose adjustment of carboplatin in patients on hemodialysis Med Oncol 31 2014 848